Brief: Paion reports positive remimazolam headline data in phase III study in procedural sedation for colonoscopy

PAION AG

20/06/2016 06:05

June 20(Reuters) - PAION AG  PA8G.DE : 
    * Said on Sunday remimazolam met its primary efficacy 
endpoint in the first study of its pivotal U.S. Phase III 
program in patients undergoing procedural sedation 
 
     
 Source text for Eikon:  urn:newsml:reuters.com:*:nEQbylDssa 
     
 Further company coverage:  PA8G.DE   
    
 
 
 (Gdynia Newsroom) 
 ((Gdynia.newsroom@thomsonreuters.com; +48 58 772 0920;))